$4.72
0.21% today
Nasdaq, Aug 12, 07:11 pm CET
ISIN
US3441741077
Symbol
FHTX

Foghorn Therapeutics Inc Stock price

$4.71
-0.69 12.78% 1M
-0.66 12.29% 6M
-0.01 0.21% YTD
-0.86 15.44% 1Y
-12.23 72.20% 3Y
-11.29 70.56% 5Y
-11.29 70.56% 10Y
-11.29 70.56% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.13 2.84%
ISIN
US3441741077
Symbol
FHTX
Industry

Key metrics

Basic
Market capitalization
$266.3m
Enterprise Value
$67.6m
Net debt
positive
Cash
$198.7m
Shares outstanding
55.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.0 | 8.8
EV/Sales
2.8 | 2.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-16.0%
Return on Equity
190.3%
ROCE
-61.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$24.2m | $30.2m
EBITDA
$-88.7m | $-93.6m
EBIT
$-91.9m | $-93.1m
Net Income
$-75.4m | $-76.6m
Free Cash Flow
$-91.3m
Growth (TTM | estimate)
Revenue
-31.3% | 33.6%
EBITDA
3.2% | 3.7%
EBIT
3.3% | 7.1%
Net Income
12.8% | 11.6%
Free Cash Flow
16.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-366.9% | -310.0%
EBIT
-380.0%
Net
-311.9% | -253.6%
Free Cash Flow
-377.8%
More
EPS
$-1.2
FCF per Share
$-1.6
Short interest
2.5%
Employees
116
Rev per Employee
$190.0k
Show more

Is Foghorn Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Foghorn Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Foghorn Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Foghorn Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Foghorn Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
24 24
31% 31%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
10% 10%
113%
- Research and Development Expense 89 89
11% 11%
367%
-89 -89
3% 3%
-367%
- Depreciation and Amortization 3.17 3.17
6% 6%
13%
EBIT (Operating Income) EBIT -92 -92
3% 3%
-380%
Net Profit -75 -75
13% 13%
-312%

In millions USD.

Don't miss a Thing! We will send you all news about Foghorn Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Foghorn Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track
Neutral
GlobeNewsWire
3 months ago
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jeff...
Neutral
GlobeNewsWire
3 months ago
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 20...
More Foghorn Therapeutics Inc News

Company Profile

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Adrian Gottschalk
Employees 116
Founded 2015
Website foghorntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today